Johnson & Johnson
JNJ: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$512.00 | Qgxw | Cpwvmmnm |
Johnson & Johnson Earnings: Broad Portfolio Strength Drives Solid Results
Johnson & Johnson reported stronger second-quarter results than we had projected and raised 2023 guidance, but we don't expect any major changes to the firm's fair value estimate based on the slight outperformance.